Zacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million
Equities research analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to post sales of $1.91 million for the current quarter, Zacks reports. Two analysts have made estimates for Celldex Therapeutics’ earnings, with the highest sales estimate coming in at $2.11 million and the lowest estimate coming in at $1.70 million. Celldex Therapeutics posted sales of $1.87 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.1%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, March 13th.
On average, analysts expect that Celldex Therapeutics will report full-year sales of $1.91 million for the current year, with estimates ranging from $11.00 million to $11.40 million. For the next financial year, analysts expect that the company will post sales of $20.30 million per share, with estimates ranging from $6.50 million to $34.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. During the same period last year, the firm posted ($0.29) earnings per share. The business’s revenue for the quarter was up 77.3% on a year-over-year basis.
Large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new stake in Celldex Therapeutics in the 3rd quarter worth approximately $101,000. BB&T Securities LLC bought a new stake in Celldex Therapeutics in the 2nd quarter worth approximately $117,000. OxFORD Asset Management LLP bought a new stake in Celldex Therapeutics in the 3rd quarter worth approximately $122,000. Voya Investment Management LLC increased its stake in Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 7,499 shares during the last quarter. Finally, Overbrook Management Corp bought a new stake in Celldex Therapeutics in the 2nd quarter worth approximately $139,000. 51.37% of the stock is currently owned by institutional investors and hedge funds.
Celldex Therapeutics (NASDAQ:CLDX) opened at $2.86 on Tuesday. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $4.91.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/21/zacks-brokerages-expect-celldex-therapeutics-inc-cldx-will-post-quarterly-sales-of-1-91-million.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.